Coombe, chairman of the FTSE 100 finance directors group, will sit on the main board of a company that will have a combined market capitalisation of approximately £114bn. It will be one of Europe’s largest companies by market capitalisation.
The deal is expected to be completed by the summer. The two companies are thought to have resumed merger talks because a big obstacle to a smooth marriage will be removed when SmithKline chief executive Jan Leschly steps down in April.
Animosity between Leschly and Glaxo executive chairman Richard Sykes was seen as the main hurdle to an earlier pact.
The merger will create a group with combined sales from continuing businesses of approximately £15bn, and an estimated 7.3% share of the global pharmaceutical market.
The two partners, both of which are audited by PricewaterhouseCoopers, expect the deal to generate £1bn in annual pre-tax cost savings from the third anniversary of completion of which £250m is expected to be reinvested in R&D.
Andrew Tyrie airs views on the Finance Bill, 'Making Tax Policy Better' report, and Brexit
In our latest managing partner Q&A looking towards 2017, CVR Global's Richard Toone talks about recruitment, and the potential threat of competition from the legal sector, as key issues for the firm in the coming year
Deloitte to avoid tendering for government contracts over the next six months, to appease Theresa May following consultant's report that painted a less-than-flattering picture of Brexit plans
In our first Q&A looking towards 2017, Menzies senior partner Julie Adams flags up increasing digitisation, aligned with more hands-on consultative services, as the key mix for her practice